Profile data is unavailable for this security.
About the company
Radiopharm Theranostics Limited is an Australia-based clinical-stage company developing a platform of radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. It has a pipeline of differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer, in pre-clinical and clinical stages of development from some of the universities and institutes around the world. The clinical program includes one Phase II and two Phase I trials in a variety of solid tumor cancers including lung, pancreas and brain. Its technologies include Nano-mAbs, Pivalate, AVB6 Integrin, PSA-mAb, DUNP19 and PTPu. Nano-mAbs is a radiopharmaceutical platform made using genetic engineered camelid derived single domain antibodies (sdAb) labelled with a radioisotope of therapeutic radiation. Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate that utilizes the early steps of fatty acid oxidation.
- Revenue in AUD (TTM)299.23k
- Net income in AUD-47.95m
- Incorporated2021
- Employees--
- LocationRadiopharm Theranostics LtdLevel 3, 62 Lygon Street, CarltonMELBOURNE 3053AustraliaAUS
- Phone+61 39824-5254
- Websitehttps://radiopharmtheranostics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oncosil Medical Ltd | 583.20k | -11.91m | 31.32m | 2.00 | -- | 4.92 | -- | 53.70 | -0.0054 | -0.0054 | 0.0003 | 0.0014 | 0.0641 | -- | 3.12 | -- | -130.97 | -67.66 | -162.31 | -77.45 | -158.87 | -- | -2,042.81 | -768.23 | -- | -- | 0.0147 | -- | 35.54 | -31.37 | -5.03 | -- | 67.76 | -- |
| Little Green Pharma Ltd | 25.63m | -8.15m | 39.37m | -- | -- | 0.505 | -- | 1.54 | -0.0272 | -0.0272 | 0.0856 | 0.2574 | 0.2772 | 1.05 | 12.29 | -- | -8.82 | -- | -9.74 | -- | 53.18 | -- | -31.81 | -- | 1.39 | -18.90 | 0.0624 | -- | 29.07 | -- | 4.72 | -- | -- | -- |
| Next Science Ltd | 35.68m | -20.67m | 39.44m | -- | -- | 3.64 | -- | 1.11 | -0.0769 | -0.0769 | 0.1309 | 0.0371 | 1.97 | 5.34 | 8.04 | -- | -113.88 | -74.40 | -168.92 | -90.31 | 78.83 | 76.98 | -57.93 | -128.26 | 1.96 | -- | 0.1045 | -- | 89.36 | 50.80 | -28.29 | -- | -2.28 | -- |
| Starpharma Holdings Ltd | 9.76m | -8.17m | 43.90m | 50.00 | -- | 1.54 | -- | 4.50 | -0.0198 | -0.0198 | 0.0237 | 0.0682 | 0.2195 | 0.244 | 1.20 | -- | -18.37 | -27.20 | -24.10 | -33.05 | 93.52 | 77.48 | -83.69 | -269.74 | 4.58 | -- | 0.1115 | -- | 131.84 | 29.10 | 47.79 | -- | -22.29 | -- |
| Medical Developments International Ltd | 33.15m | -40.99m | 47.88m | 68.00 | -- | 0.8234 | -- | 1.44 | -0.4627 | -0.4627 | 0.3741 | 0.5162 | 0.4131 | 1.02 | 4.14 | -- | -51.09 | -15.81 | -60.56 | -17.79 | 73.50 | 70.98 | -123.66 | -52.49 | 1.82 | -- | 0.0476 | -- | 2.51 | 9.22 | -630.83 | -- | -20.32 | -- |
| Inoviq Ltd | 791.70k | -6.55m | 50.74m | 85.00 | -- | 2.40 | -- | 64.10 | -0.0709 | -0.0709 | 0.0086 | 0.1894 | 0.0366 | 4.54 | 0.6418 | -- | -30.33 | -44.62 | -32.64 | -47.55 | 89.77 | -- | -827.88 | -1,928.52 | 7.06 | -- | 0.0198 | -- | 5.29 | 146.33 | 26.92 | -- | -- | -- |
| Vitura Health Ltd | 123.87m | 3.51m | 56.44m | 119.00 | 15.88 | 1.46 | 11.55 | 0.4556 | 0.0062 | 0.0062 | 0.2165 | 0.0674 | 2.10 | 15.04 | 10.74 | 1,040,932.00 | 5.50 | 13.50 | 7.70 | 18.51 | 27.63 | 32.41 | 2.62 | 6.19 | 1.11 | 30.48 | 0.2228 | -- | 5.56 | -- | -74.57 | -- | 155.80 | -- |
| Radiopharm Theranostics Ltd | 299.23k | -47.95m | 56.50m | -- | -- | 0.4256 | -- | 188.81 | -0.1261 | -0.1261 | 0.0008 | 0.0611 | 0.0041 | -- | 0.1097 | -- | -65.24 | -- | -82.85 | -- | -- | -- | -16,024.17 | -- | -- | -3.91 | 0.00 | -- | 2.35 | -- | -38.54 | -- | -- | -- |
| Syntara Ltd | 5.43m | -13.67m | 63.16m | 107.00 | -- | 11.74 | -- | 11.64 | -0.0157 | -0.016 | 0.0057 | 0.0039 | 0.3155 | -- | 0.7918 | -- | -79.44 | -30.68 | -130.63 | -40.26 | -- | -- | -251.77 | -74.66 | -- | -484.90 | 0.0474 | -- | -7.92 | -15.43 | -1.77 | -- | -62.79 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Investors Mutual Ltd.as of 31 Oct 2024 | 43.68m | 2.01% |
